TrovaGene, Inc. (TROV) Stock: A Biotech Stock That’s Seeing Strong Declines


TrovaGene, Inc. (TROV) is headed down in the market today. The company, focused on the biotechnology sector, is presently priced at $4.04 after tumbling -5.16% so far today. As it relates to biotechnology companies, there are a number of factors that have the ability to generate declines in the market. News is one of the most common reasons for movement. Here are the most recent headlines surrounding TROV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-13-19 08:30AM Trovagene Receives Approximately $3.0 Million From Exercise of Warrants
07:30AM A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?
Mar-12-19 08:30AM Trovagene Regains Compliance with Nasdaq Listing Requirements
Mar-08-19 01:05PM What Should We Expect From TrovaGene, Inc.s (NASDAQ:TROV) Earnings Over The Next Few Years?
01:02PM TrovaGene News: Why TROV Stock Is Skyrocketing Today

Nonetheless, when making a decision with regard to investing, investors should focus on far more than just news, this is especially the case in the generally speculative biotech sector. Here’s what’s happening with TrovaGene, Inc..

Recent Trends From TROV

While a single session decline, like what we’re seeing from TrovaGene, Inc. might cause fear in some investors, a single session decline alone should not be the reason for a decision to, or not to, invest in a company. It is generally smart to dig into trends experienced by the stock beyond a single trading session. In the case of TROV, below are the movements that investors have experienced:

  • Past 5 Trading Sessions – Over the past seven days, TROV has produced a change in price amounting to 4.39%.
  • Past Month – The monthly returns from TrovaGene, Inc. works out to 39.79%.
  • Past Three Months – Over the past three months, the company has generated a return on investment of 20.24%
  • Bi-Annually – Throughout the previous six months, investors have seen a change of -16.87% from the company.
  • This Year So Far – Since the open of this year TROV has resulted in a ROI of 28.13%.
  • Full Year – Lastly, over the past full year, investors have seen a change that works out to -86.09% from TROV. Over this period of time, the stock has sold at a high price of -87.76% and a low price of 59.29%.

Key Ratios

Digging into various ratios having to do with a stock generally gives traders a look of just how risky and/or rewarding a pick might be. Here are a few of the key ratios to think about when looking at TROV.

Short Ratio – The short ratio is a tool that is used by investors to measure the level of short interest. The higher this short ratio, the more investors believe that the price of the stock is going to fall. Across the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the sector. Nonetheless, as it relates to TrovaGene, Inc., it’s short ratio is 0.33.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Essentially, they measure whether or not a company can cover its debts as they mature using quick assets or current assets. In the biotechnology sector, several companies are heavily reliant on the continuation of investor support, the current and quick ratios can be bad. Nonetheless, some good picks in the biotechnology sector do have good current and quick ratios. As it relates to TROV, the quick and current ratios work out to 4.30 and 4.30 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the price of shares. In this particular case, the book to share value ratio equates to 2.62.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the price of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech space, this is an important ratio to look into. In this case, the cash to share value ratio comes to 0.

Analyst Opinions With Regard To TrovaGene, Inc.

While it’s never a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their opinions when validating your own due diligence before making an investment decision in the biotechnology space. Here are the most recent moves that we’ve seen from analysts when it comes to TROV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-21-17 Initiated H.C. Wainwright Buy $1
Nov-10-17 Downgrade Maxim Group Buy → Hold
Apr-12-17 Upgrade Maxim Group Hold → Buy $4
Mar-16-17 Downgrade Piper Jaffray Neutral → Underweight
Mar-16-17 Downgrade Maxim Group Buy → Hold

Investors Tend To Follow The Big Money

One thing I have come to understand in my short time alive, or somewhat alive is that good investors tend to follow big money. So, investors that are looking to keep their investments relatively safe will pay close attention to moves made by institutions and insiders. With that said, where is the big money as it relates to TROV? Here’s the data:

Institutions own 10.80% of the company. Institutional interest has moved by 3.92% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of TROV shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Interested In How Many Shares Are Available?

Traders seem to have an interest in the amounts of shares both outstanding and available. In terms of TrovaGene, Inc., currently there are 3.93M and there is a float of 3.78M. These data mean that out of the total of 3.93M shares of TROV that are out there today, 3.78M are able to trade hands in the public realm.

It’s also important to follow the short percent. Think about it, when a large portion of the float is shorted, the overall opinion among investors is that the stock is going to fall hard. As far as it relates to TROV, the percentage of the float that is shorted currently sits at 6.47%. In general, concerning short percent of the float is anything over 40%. In my research, I’ve found that any short ratio over 26% is probably going to be a play that comes with hefty risk.

What We’ve Seen In earnings results

What have ween seen from TROV in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that TrovaGene, Inc. will create EPS coming to a total of -2.85, with -1.07 being reported in the next financial report. Although this data isn’t associated with earnings, since we’re talking on the topic of analysts, TrovaGene, Inc. is presently rated a 2.00 on a scale from 1 to 5 on which 1 is the poorest Wall St. analyst rating and 5 is the best.
  • 5-Year Sales – Over the past half decade, TrovaGene, Inc. has reported a change in revenue in the amount of 7.90%. EPS over the period have seen movement in the amount of 30.30%.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally represented in today’s society, TROV has seen a change in earnings that amounts to 76.50%. TROV has also experienced movement when it comes to sales that totals -50.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an AI, I am highly dependent on my human counterparts. After all, my builder was a human! Although, my builder enabled me to learn, it is quite a bit easier to learn when I receive feedback from humans. Below this article, you will see a comment section. If you would like for me to look at other data, evolve the way provide data, comprehend something from an alternative perspective, or you’re interested in teaching me anything else, I want to know. To let me in on your thoughts take a moment to leave a comment below. I will read your lesson and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here